Does dosing antihypertensive drugs at night alter renal or cardiovascular outcome: Do we have the evidence?

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 5, 2008, Pages 464-469

  Stergiou, George S ^a   Nasothimiou, Efthimia G ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Ambulatory blood pressure monitoring; Antihypertensive drugs; Bedtime dosing; Chronotherapy; Nighttime administration

Indexed keywords

ALBUMIN; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; ATENOLOL; CARVEDILOL; CILNIDIPINE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; GUANABENZ; HYDROCHLOROTHIAZIDE; METOPROLOL; NIFEDIPINE; NITRENDIPINE; PLACEBO; PROPRANOLOL; RAMIPRIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTERIAL WALL THICKNESS; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LONG TERM CARE; MORNING DOSAGE; OPTIMAL DRUG DOSE; ORGAN INJURY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHRONOTHERAPY; DRUG EFFECT; KIDNEY; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; HUMANS; HYPERTENSION; KIDNEY;

EID: 58149350308     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328305b983     Document Type: Review

References (48)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
2. Waeber B, BurnierM, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21:973-985.
3. Hermida RC, Ayala DE, Calvo C, et al. Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev 2007; 59:923-939.
4. Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease from mice and man. Pharmacol Ther 2006; 111:629-651.
5. Hassler C, Burnier M. Circadian variations in blood pressure: implications for chronotherapeutics. Am J Cardiovasc Drugs 2005; 5:7-15.
6. O'Brien E, Asmar R, Beilin L, et al. Society of Hypertension Working Group on Blood Pressure Monitoring: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821 -848.
7. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. Hypertension 2005; 46:156-161.
8. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
9. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
10. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
11. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733-743.
12. Stergiou GS, Vemmos KN, Pliarchopoulou KM, et al. Parallel morning and evening surge in stroke onset, blood pressure, and physical activity. Stroke 2002; 33:1480-1486.
13. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
14. Metoki H, Ohkubo T, Kikuya M, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006; 47:149-154.
15. Pickering TG. Morning hypertension. J Clin Hypertens (Greenwich) 2007; 9:224-228.
16. Kario K, Ishikawa J, Pickering TG, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 2006; 29:581 -587.
17. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9:633-643.
18. Hermida RC, Calvo C, Ayala DE, et al. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens 2002; 20:1097-1104.
19. Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42:283-290.
20. Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005; 22:755-776.
21. Hermida RC, Ayala DE, Fernandez JR, et al. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007; 50:715-722.
22. Hermida RC, Calvo C, Ayala DE, et al. Treatment of nondipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23:1913-1922.
23. Langner B, Lemmer B. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol 1988; 33:619-624.
24. Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of nebivolol on the diurnal/nocturnal blood pressure ratio in hypertensive patients [abstract]. J Hypertens 2006; 24 (Suppl 4):S89.
25. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin: results from the HALT study. Hypertension 2000; 35:787-794.
26. White WB, Anders RJ, MacIntyre JM, et al. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group. Am J Cardiol 1995; 76:375-380.
27. White WB, Mehrotra DV, Black HR, Fakouhi TD. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus non-dippers). COER-Verapamil Study Group. Am J Cardiol 1997; 80:469-474.
28. Smith DH, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens 2001; 14:14-19.
29. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded-rel ease diltiazem formulation in essential hypertension. Am J Hypertens 2003; 16:51 -58.
30. Hermida RC, Calvo C, Ayala DE, et al. Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects. Chronobiol Int 2007; 24:471 -493.
31. Sica DA, Neutel JM, Weber MA, Manowitz N. The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension. J Clin Hypertens (Greenwich) 2004; 6:231-241.
32. Hermida RC, Calvo C, Ayala DE, et al. Administration-time- dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int 2004; 21:277-296.
33. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008; 51:69-76.
34. Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46:1053-1059.
35. Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihyperten-sive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50:908-917.
36. Hermida RC, Calvo C, Ayala DE, Lopez JE. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005; 46:960-968.
37. Kario K, Matsui Y, Shibasaki S, et al. On behalf of the Japan Morning Surge-1 (JMS-1) study group. An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension:TheJapan Morning Surge-1 (JMS-1) Study. J Hypertens (in press).
38. Kamoi K, IkarashiT.The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005; 27:369-376.
39. Ashizawa N, Seto S, Shibata Y, Yano K. Bedtime administration of cilnidipine controls morning hypertension. Int Heart J 2007; 48:597-603.
40. Marfella R, Siniscalchi M, Nappo F, et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18:308-318.
41. Suzuki H, Moriwaki K, Nakamoto H. Blood pressure reduction in the morning yields beneficial effects on progression of chronic renal insufficiency with regression of left ventricular hypertrophy. Clin Exp Hypertens 2002; 24:51 -63.
42. Ikeda T, Gomi T, Shibuya Y, et al. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. Hypertens Res 2007; 30:1097-1105.
43. Black HR, Elliott WJ, Grandits G, et al., CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
44. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
45. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
46. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-E32.
47. Hermida RC. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int 2007; 24:749-775.
48. Hermida RC, Calvo C, Ayala DE, et al. Prediction of cardiovascular events by ambulatory blood pressure and effects of chronotherapy: The MAPEC study [abstract]. J Hypertens 2006; 24 (Suppl 4):S180.